Open AccessAdverse Events of Sodium–Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review
Author(s) -
Hojong Choi,
Leigh-Anh Nguyen,
Jin-Yi Wan,
Hooman Milani,
Kristine McGill,
Jong Park
Publication year - 2021
Publication title -
the permanente journal/permanente journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.445
H-Index - 30
eISSN - 1552-5775
pISSN - 1552-5767
DOI - 10.7812/tpp/20.242
Subject(s) - medicine , kidney disease , renal function , creatinine , diabetic ketoacidosis , diabetes mellitus , adverse effect , type 2 diabetes , acute kidney injury , retrospective cohort study , surgery , endocrinology
The renal benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2) are now well established, and these agents are recommended by the American Diabetes Association and Kidney Disease: Improving Global Outcomes guidelines for patients with type 2 diabetes and chronic kidney disease. However, the safety profile of SGLT2 inhibitors in chronic kidney disease is not as clear. We describe the adverse event rates of SGLT2 inhibitors, primarily empagliflozin, in Kaiser Permanente Southern California members with diabetic kidney disease.